Immunogenicity of Guselkumab (GUS) Among Psoriasis Patients in VOYAGE (VOY) 1&amp;2 Studies

Kristian Reich; April W. Armstrong; Yaowei Zhu; Megan Miller; Yin You; Yaung‐Kaung Shen; Ya‐Wen Yang; Peter Foley; Christopher Em Griffiths; Bruce Strober

doi:10.25251/skin.6.supp.11

Related publications

Letter2023

Immunogenicity and pharmacokinetics of guselkumab among patients with moderate‐to‐severe psoriasis in VOYAGE‐1 and VOYAGE‐2

April W. Armstrong, Kilian Eyerich, Curdin Conrad, Yihong Zhu, Ya‐Wen Yang, Megan Miller, Yin You, Yaung‐Kaung Shen, Peter Foley, Christopher Em Griffiths, Bruce Strober

Article2017

Efficacy of guselkumab in subpopulations of patients with moderate‐to‐severe plaque psoriasis: a pooled analysis of the phase <scp>III VOYAGE</scp> 1 and <scp>VOYAGE</scp> 2 studies

Kenneth B. Gordon, Andrew Blauvelt, Peter Foley, Michael Song, Yasmine Wasfi, B. Randazzo, Yaung‐Kaung Shen, Yin You, Christopher Em Griffiths

Article2020

15308 Frequency of gastrointestinal-related serious adverse events among guselkumab-treated patients with moderate to severe psoriasis: A pooled analysis of Voyage 1 and Voyage 2 through 3 years

Peter Foley, Kristian Reich, Andrew Blauvelt, Jerry Bagel, Richard G. Langley, Michael Song, Paraneedharan Ramachandran, Yaung‐Kaung Shen, Yin You, Mark Lebwohl, Christopher Em Griffiths

Article2020

15287 Comparisons of symptom-free and sign-free status among patients with moderate to severe plaque psoriasis treated with guselkumab or adalimumab: Results from VOYAGE 1

Christopher Em Griffiths, Sandra Philipp, Jerry Bagel, Chenglong Han, Michael Song, Yu‐Huei Huang, David N. Adam, Tina Bhutani, Andrew Blauvelt

Article2020

Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1

Christopher Em Griffiths, Kim Papp, Michael Song, Megan Miller, Yin You, Yaung‐Kaung Shen, Chenglong Han, Andrew Blauvelt

Immunogenicity of Guselkumab (GUS) Among Psoriasis Patients in VOYAGE (VOY) 1&2 Studies

Abstract

Discussion(0)

Related publications

Immunogenicity and pharmacokinetics of guselkumab among patients with moderate‐to‐severe psoriasis in VOYAGE‐1 and VOYAGE‐2

Efficacy of guselkumab in subpopulations of patients with moderate‐to‐severe plaque psoriasis: a pooled analysis of the phase <scp>III VOYAGE</scp> 1 and <scp>VOYAGE</scp> 2 studies

15308 Frequency of gastrointestinal-related serious adverse events among guselkumab-treated patients with moderate to severe psoriasis: A pooled analysis of Voyage 1 and Voyage 2 through 3 years

15287 Comparisons of symptom-free and sign-free status among patients with moderate to severe plaque psoriasis treated with guselkumab or adalimumab: Results from VOYAGE 1

Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1

Immunogenicity of Guselkumab (GUS) Among Psoriasis Patients in VOYAGE (VOY) 1&amp;2 Studies

Abstract

Discussion(0)

Related publications

Immunogenicity and pharmacokinetics of guselkumab among patients with moderate‐to‐severe psoriasis in VOYAGE‐1 and VOYAGE‐2

Efficacy of guselkumab in subpopulations of patients with moderate‐to‐severe plaque psoriasis: a pooled analysis of the phase <scp>III VOYAGE</scp> 1 and <scp>VOYAGE</scp> 2 studies

15308 Frequency of gastrointestinal-related serious adverse events among guselkumab-treated patients with moderate to severe psoriasis: A pooled analysis of Voyage 1 and Voyage 2 through 3 years

15287 Comparisons of symptom-free and sign-free status among patients with moderate to severe plaque psoriasis treated with guselkumab or adalimumab: Results from VOYAGE 1

Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1

Immunogenicity of Guselkumab (GUS) Among Psoriasis Patients in VOYAGE (VOY) 1&2 Studies